FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced new, long-term data from open-label extensions (OLE) of two Phase 3 studies (Study 1489 and Study 1490) of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/teno… […]
SAN JOSE, Calif., March 05, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detecti… […]
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases incl… […]
EMERYVILLE, Calif.–(BUSINESS WIRE)–Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees restricted stock units to acquire 57,000 shares of the compan… […]
Among the dozens of countries that reduced their emissions 2016-2019, carbon dioxide emissions fell at roughly one-tenth the rate needed worldwide to hold global warming well below 2°C relative to preindustrial levels, a new study finds. […]
One of biotech’s earliest SPAC investors is back with another blank-check company, less than a month after his last effort announced its intent to merge.
Rajiv Shukla is intending to take a third lucky winner public with Alpha Healthcare Acquisition II… […]
Lilli Petruzzelli
→ A spokesperson for Genentech tells Endpoints News that Lilli Petruzzelli has forged a new path this week as SVP, early clinical development at Genentech’s Research and Early Development organization (gRED). Petruzzelli just spent tw… […]
At the heart of all efforts is research centered on a truism: Women are different than men. But studies don’t necessarily always show how a drug, device or diagnostic works differently in the genders.
Three women and one groundbreaking biological technology are at the center of Lycia Therapeutics.
Just a day after GlaxoSmithKline and Vir Biotechnology’s Covid-19 antibody fell flat in an NIH-sponsored trial for hospitalized patients, researchers have ejected another therapy from the study. Is this the death knell for monoclonal antibodies for tho… […]
Copyright © 2021 | MH Magazine WordPress Theme by MH Themes
